Dangerous New Kratom Derivative: 7-OH
Introduction
7-Hydroxymitragynine, commonly called 7-OH or 7-HMG, is a potent opioid-active compound associated with the kratom plant. Although 7-OH occurs naturally in kratom in trace amounts, concentrated products containing added or enhanced levels of 7-OH are increasingly sold as tablets, gummies, drink mixes, shots, and other products.
The FDA warns that concentrated 7-OH products are potent opioid products that have not been proven safe or effective for any medical use. Federal regulators have also taken steps toward controlling certain high-concentration 7-OH products because of concerns about dependence, withdrawal, and other serious adverse effects. FDA - Products Containing 7-OH Can Cause Serious Harm
If you or someone you care about is using concentrated 7-OH regularly, understanding the signs of dependence, withdrawal, and overdose risk can help you know when professional evaluation may be appropriate.
What Is 7-OH Kratom and How Is It Different From “Regular” Kratom?
7-OH, or 7-hydroxymitragynine, is a naturally occurring alkaloid found in very small amounts in the kratom plant. Kratom also contains mitragynine, its most abundant alkaloid.
Traditional kratom products made from whole or minimally processed leaf generally contain only trace amounts of 7-OH. In contrast, some newer commercial products contain added, concentrated, or enhanced levels of 7-OH, which can produce much stronger opioid-like effects.
Laboratory and preclinical studies suggest that 7-OH has significantly greater activity at opioid receptors than mitragynine and may be more potent than morphine in some experimental models. That does not mean every 7-OH product is directly equivalent to a specific dose of morphine, because product strength and human effects can vary widely.
Federal concern has focused primarily on high-concentration 7-OH products, not traditional kratom leaf itself. The FDA has warned that these concentrated products may carry risks of dependence, withdrawal, overdose, and other serious adverse effects. FDA — Products Containing 7-OH Can Cause Serious Harm
Recent Federal Action on 7-OH
Federal regulators have taken increasing action against concentrated and synthetic 7-OH products.
In July 2025, the FDA recommended that certain 7-OH products be controlled under the federal Controlled Substances Act because of their opioid-like effects, abuse potential, and lack of an approved medical use. DEA Press Release
In July 2026, the DEA announced the start of the temporary scheduling process for 7-OH above a proposed concentration threshold, along with three related synthetic compounds. The agencies emphasized that the action is aimed at concentrated or synthetic 7-OH products and is not intended to apply to traditional kratom leaf containing only naturally occurring trace amounts of 7-OH. FDA- Hiding in Plain Sight: 7-OH Products
As of September 2026, the federal process involving the proposed 7-OH threshold is still underway. HHS extended the public comment period on that threshold through September 10, 2026. FDA- Hiding in Plain Sight: 7-OH Products
Why 7-OH Can Be Dangerous
7-OH acts on mu-opioid receptors, the same receptor system involved in the effects of opioids such as morphine and fentanyl. Because concentrated 7-OH products can produce strong opioid-like effects, the FDA has raised concerns about their potential for dependence, withdrawal, respiratory depression, seizures, and other serious adverse effects.
Risk may be greater with products containing added or enhanced concentrations of 7-OH, particularly because product strength can vary and consumers may not always know exactly how much 7-OH they are taking. The FDA has specifically warned consumers to avoid concentrated 7-OH products sold as tablets, gummies, drink mixes, shots, and similar products.
Combining 7-OH with other substances that depress the central nervous system, including alcohol, benzodiazepines, or other opioids, may further increase the risk of serious sedation and breathing problems. FDA- Products Containing 7-OH Can Cause Serious Harm
Warning Signs of 7-OH Dependence and Withdrawal
Regular use of concentrated 7-OH products can lead to tolerance, physical dependence, and withdrawal. Signs that use may be becoming problematic can include:
Needing larger or more frequent amounts to get the same effect
Strong cravings or preoccupation with obtaining 7-OH
Difficulty cutting down or stopping
Restlessness, irritability, body aches, fatigue, insomnia, sweating, or gastrointestinal symptoms when use is reduced or stopped
Continuing to use despite negative effects on daily life, relationships, work, or health
Spending increasing amounts of time obtaining, using, or recovering from 7-OH
The FDA has received reports involving addiction, anxiety, depression, gastrointestinal distress, insomnia, seizures, and withdrawal symptoms associated with 7-OH products. FDA- Products Containing 7-OH Can Cause Serious Harm
Possible Overdose Warning Signs
Because 7-OH has opioid-like effects, signs of a serious opioid-type overdose may include:
Inability to wake up or unresponsiveness
Slow, shallow, or stopped breathing
Choking, gurgling, or unusual snoring sounds in someone who cannot be awakened
Small, constricted “pinpoint” pupils
Discoloration of the lips, fingernails, or skin
If you suspect an overdose, administer naloxone if available and call 911 immediately. Stay with the person until emergency medical help arrives. CDC- 5 Things to Know About Naloxone
What Detox May Look Like for 7-OH
Because 7-OH acts on opioid receptors, withdrawal can resemble opioid withdrawal. Reported symptoms may include:
Restlessness and irritability
Body aches
Sweating or chills
Nausea, vomiting, or gastrointestinal distress
Insomnia
Anxiety
Cravings
The severity of withdrawal can vary depending on the amount used, frequency of use, length of use, other substances involved, and individual health factors. The FDA has received reports of withdrawal symptoms and dependence associated with concentrated 7-OH products. FDA- Products Containing 7-OH Can Cause Serious Harm
There is currently no standardized FDA-approved detox protocol specifically for 7-OH withdrawal. Treatment should be individualized after clinical evaluation. Published case reports and a small 2026 case series have described the use of buprenorphine for some people with problematic 7-OH use, but more research is needed before it can be considered a standard approach. PubMed — Buprenorphine for the Management of 7-Hydroxymitragynine (7-OH) Use: A Retrospective Case Series
A structured detox setting can provide ongoing withdrawal monitoring, 24/7 staff support, provider-directed medication management when appropriate, and coordination with medical providers while determining what continuing treatment may be needed.What to Do if You Suspect 7-OH Exposure or Dependence
Seek a clinical evaluation as soon as possible—assessment clarifies level of dependence, co-occurring conditions, and safest detox path.
Avoid unregulated products; many 7-OH items are mislabeled or produced with unknown potency.
Consider medically supervised detox with MAT options to stabilize safely.
Build a support plan: identify friends/family, therapy, and aftercare.
Educate close contacts about overdose recognition and naloxone availability. U.S. Food and Drug Administrationhttps://www.wsaw.com
What to Do if You Suspect 7-OH Dependence
If you or someone you care about is using concentrated 7-OH regularly and having difficulty stopping, consider taking these steps:
Seek a professional evaluation. A qualified treatment provider can review the amount and frequency of use, withdrawal symptoms, other substances being used, and whether detox or another level of care may be appropriate.
Avoid taking additional unregulated 7-OH products to manage withdrawal. Product strength and composition can vary, and concentrated 7-OH products have not been approved by the FDA as safe or effective for treating withdrawal or any other medical condition. FDA — Products Containing 7-OH Can Cause Serious Harm
Do not assume every 7-OH withdrawal should be treated the same way. Treatment should be individualized. Medication may be considered by a medical provider when clinically appropriate, but there is not yet a standardized FDA-approved detox protocol specifically for 7-OH.
Know the signs of a medical emergency. If someone is unresponsive, has slow or stopped breathing, or appears to be experiencing an overdose, call 911 immediately. Naloxone may help reverse opioid-type effects and should be administered if available.
Plan for continued treatment after detox. Withdrawal management is only one part of recovery. Residential treatment, counseling, medication when appropriate, and ongoing recovery support may help address continued substance use and reduce the risk of returning to use.
Why Salterra OC Detox & Treatment Can Help
Salterra OC Detox & Treatment offers a private, six-bed detox and residential treatment setting in Orange County for individuals who need a structured environment while beginning recovery from substance use.
For someone experiencing dependence on 7-OH or other substances, our approach may include:
24/7 staff support
Ongoing withdrawal monitoring
Provider-directed medication management when appropriate
Coordination with medical providers
Individualized treatment planning
Residential support following detox when clinically appropriate
Because 7-OH products can vary significantly in strength and composition, treatment should be based on the individual’s use history, current symptoms, and overall needs rather than a one-size-fits-all protocol.
If you or someone you care about is struggling to stop using 7-OH, our admissions team can help you understand the available options and determine whether Salterra may be an appropriate fit.
If you’re noticing dependence or experiencing withdrawal, don’t wait—reach out for a confidential consultation and get the structured support you need to begin healing.!